Christine Blank
Contributing Editor Christine Blank is a freelance writer based in Florida.
CVS, Cigna on board with generic EpiPens
The urgent need for a less-expensive epinephrine auto-injector is now being addressed.
Generics and biosimilars, key to Trump drug price concerns
If pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group.
Long-acting opioid painkiller wins approval
FDA recently approved a long-acting opioid designed to deter abuse.
Trump's drug pricing comments create debate
While President-elect Donald Trump recently said that the pharmaceutical industry is “getting away with murder” in terms of drug prices, the industry is trying to self-regulate before facing tighter rules from the incoming administration.
Report: Pharmacists dispensing dangerous drug combos
Walgreens, CVS Health and other drug chains promised to improve procedures after a Chicago Tribune investigation found that pharmacists at several retail chains filled prescriptions with dangerous drug combinations.
Walgreens faces anti-tobacco effort ahead of annual meeting
Two organizations opposed to tobacco sales at pharmacy chains are turning their attention to Walgreens’ annual shareholder meeting on January 26.
New 340B drug rule sets drugmaker fines
Consumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.
FDA approves hemophilia A drug for children
FDA recently expanded the use of antihemophilic factor (recombinant), pegylated (Adynovate, Shire plc) for hemophilia A patients under 12 years old.
New device could be breakthrough for diabetics
FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics.
Why 2016 drug approvals fell
Why 2016 drug approvals fell
While FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.

Poll

View Results